Product Information
RYALTRIS 665-25 MCG SPRAY is a brand product labeled by Hikma Specialty USA Inc., priced at $7.6715 per GM under NDC 59467070027. Its NADAC has been published 181 times since Apr 19, 2023.
FDA first approved this application on Jan 13, 2022.
Strength
25; 665 ug/1; ug/1
Manufacturer
Hikma Specialty USA Inc.NDC
59467070027
Classification
Brand
Dosage Form
SPRAY, METERED
Route
NASAL
Effective Date
9/23/2026
Active Ingredients
MOMETASONE FUROATE MONOHYDRATE; OLOPATADINE HYDROCHLORIDEApproval Type
New Drug (NDA)
FDA Application
NDA211746FDA Approved
1/13/2022
On Market Since
8/15/2022
Pharmacological Classes
Price Statistics
The NADAC for RYALTRIS 665-25 MCG SPRAY has been published 181 times since Apr 19, 2023, and over the history we have for it it has declined 7.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $7.6715 per GM |
|---|---|
| All-time high | $8.2588 (Aug 16, 2023) |
| All-time low | $7.6684 (Jun 17, 2026) |
| 52-week high | $8.2207 |
| 52-week low | $7.6684 |
| Median price | $8.2232 |
| Average price | $8.1224 |
| Largest weekly change | -6.5% (Feb 18, 2026) |
| Weeks tracked | 181 |
| Tracking since | Apr 19, 2023 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the olopatadine hydrochloride and mometasone furoate market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Hikma Specialty USA Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
olopatadine hydrochloride and mometasone furoate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Corticosteroid class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of RYALTRIS 665-25 MCG SPRAY?
The current National Average Drug Acquisition Cost (NADAC) for RYALTRIS 665-25 MCG SPRAY, manufactured by Hikma Specialty USA Inc., is $7.6715 per GM (NDC 59467070027), effective Sep 30, 2026.
How has the price of RYALTRIS 665-25 MCG SPRAY changed over time?
Over the history we have for it, the NADAC for RYALTRIS 665-25 MCG SPRAY has declined 7.1%. It has been tracked across 181 weekly CMS publications since Apr 19, 2023.
What are the highest and lowest recorded NADAC prices for RYALTRIS 665-25 MCG SPRAY?
Since Apr 19, 2023, the NADAC for RYALTRIS 665-25 MCG SPRAY has ranged from a low of $7.6684 (Jun 17, 2026) to a high of $8.2588 (Aug 16, 2023), with a median of $8.2232 per GM.
Are there cheaper alternatives to RYALTRIS 665-25 MCG SPRAY?
No other NADAC-published product currently shares the active ingredient and strength of RYALTRIS 665-25 MCG SPRAY in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures RYALTRIS 665-25 MCG SPRAY?
RYALTRIS 665-25 MCG SPRAY (NDC 59467070027) is labeled by Hikma Specialty USA Inc., and CMS classifies it as a brand product.